AP 5280

Drug Profile

AP 5280

Alternative Names: AP 5070; AP5280; Polymer Platinate

Latest Information Update: 26 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of London School of Pharmacy
  • Developer Access Pharmaceuticals
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ovarian cancer

Most Recent Events

  • 26 Nov 2002 Phase-I/II clinical trials in Ovarian cancer in Europe (unspecified route)
  • 11 Sep 2000 Phase-I clinical trials for Solid tumours in Europe (unspecified route)
  • 16 Aug 2000 Preclinical data has been added to the pharmacodynamics and pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top